Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899689064> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2899689064 endingPage "S106" @default.
- W2899689064 startingPage "S106" @default.
- W2899689064 abstract "Age-related macular degeneration(AMD) is the leading cause of older adult blindness, but other common causes also needed to be discussed. Treatment the diease used intravitreous injection of vascular endothelial growth factor (VEGF) inhibitors were expensive. The purpose of this study was to analyze the cost of anti-VEGF drugs used in Taiwan. We retrospectively review outpatients with drugs of the 5th ATC code (S01LA) during Jan 2011 to Dec 2016 in Chimei medical center in Taiwan. Descriptive analysis the date of patient age, sex, and diagnosis. And total outpatients drug expense date collected over the 2011-2016 period. A total of 4,406 records were treated with anti-VEGF in our hospital in 2011 to 2016. These patients had a mean age of 67.8 years and 60% were man. Most of them was treated with ranibizumab(78.1%), followed by aflibercept(14.5%), and verteporfin(7.4%). The annual costs of anti-VEGF were increased from NT$ 5 millions in 2011 to NT$ 33 millions in 2016. The anti-VEGF drug costs accounted for 0.57%-2.48% of total drug costs for all outpatients in each year. Futher analysis, most of them were 50-59 year(drug ratio range from 0.07% in 2011 to 0.41% in 2016), followed by patients were 60-69 years(drug ratio range from 0.17% in 2011 to 0.91% in 2016); most of these patients with diagnosis were diabetic macular edema(DME)(patient number range from 13 in 2011 to 514 in 2016), followed by patients were wetAMD(patient number range from 91 in 2011 to 428 in 2016). From these rusults, we can understand during past six years, anti-VEGF drugs useage increased continuously, especially in patient who had DM with older age, so these will be the main target to control DM may decrease progression to advanced retinopathy and reduce the expenditure on drugs." @default.
- W2899689064 created "2018-11-16" @default.
- W2899689064 creator A5076512663 @default.
- W2899689064 date "2018-09-01" @default.
- W2899689064 modified "2023-09-30" @default.
- W2899689064 title "Descriptive Analysis of Drug Expense for Anti-Vascular Endothelial Growth Factor Therapy in Taiwan" @default.
- W2899689064 doi "https://doi.org/10.1016/j.jval.2018.07.805" @default.
- W2899689064 hasPublicationYear "2018" @default.
- W2899689064 type Work @default.
- W2899689064 sameAs 2899689064 @default.
- W2899689064 citedByCount "0" @default.
- W2899689064 crossrefType "journal-article" @default.
- W2899689064 hasAuthorship W2899689064A5076512663 @default.
- W2899689064 hasBestOaLocation W28996890641 @default.
- W2899689064 hasConcept C118487528 @default.
- W2899689064 hasConcept C119767625 @default.
- W2899689064 hasConcept C126322002 @default.
- W2899689064 hasConcept C167734588 @default.
- W2899689064 hasConcept C187212893 @default.
- W2899689064 hasConcept C2776403814 @default.
- W2899689064 hasConcept C2776694085 @default.
- W2899689064 hasConcept C2777025900 @default.
- W2899689064 hasConcept C2777802072 @default.
- W2899689064 hasConcept C2778749236 @default.
- W2899689064 hasConcept C2780035454 @default.
- W2899689064 hasConcept C2780929884 @default.
- W2899689064 hasConcept C2781100027 @default.
- W2899689064 hasConcept C71924100 @default.
- W2899689064 hasConcept C98274493 @default.
- W2899689064 hasConceptScore W2899689064C118487528 @default.
- W2899689064 hasConceptScore W2899689064C119767625 @default.
- W2899689064 hasConceptScore W2899689064C126322002 @default.
- W2899689064 hasConceptScore W2899689064C167734588 @default.
- W2899689064 hasConceptScore W2899689064C187212893 @default.
- W2899689064 hasConceptScore W2899689064C2776403814 @default.
- W2899689064 hasConceptScore W2899689064C2776694085 @default.
- W2899689064 hasConceptScore W2899689064C2777025900 @default.
- W2899689064 hasConceptScore W2899689064C2777802072 @default.
- W2899689064 hasConceptScore W2899689064C2778749236 @default.
- W2899689064 hasConceptScore W2899689064C2780035454 @default.
- W2899689064 hasConceptScore W2899689064C2780929884 @default.
- W2899689064 hasConceptScore W2899689064C2781100027 @default.
- W2899689064 hasConceptScore W2899689064C71924100 @default.
- W2899689064 hasConceptScore W2899689064C98274493 @default.
- W2899689064 hasLocation W28996890641 @default.
- W2899689064 hasOpenAccess W2899689064 @default.
- W2899689064 hasPrimaryLocation W28996890641 @default.
- W2899689064 hasRelatedWork W1428301736 @default.
- W2899689064 hasRelatedWork W2015993450 @default.
- W2899689064 hasRelatedWork W2320987231 @default.
- W2899689064 hasRelatedWork W2346873848 @default.
- W2899689064 hasRelatedWork W2414742053 @default.
- W2899689064 hasRelatedWork W2553987180 @default.
- W2899689064 hasRelatedWork W2778969273 @default.
- W2899689064 hasRelatedWork W2786851228 @default.
- W2899689064 hasRelatedWork W3028842049 @default.
- W2899689064 hasRelatedWork W4243304339 @default.
- W2899689064 hasVolume "21" @default.
- W2899689064 isParatext "false" @default.
- W2899689064 isRetracted "false" @default.
- W2899689064 magId "2899689064" @default.
- W2899689064 workType "article" @default.